BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29678874)

  • 1. Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
    Teijeira A; Labiano S; Garasa S; Etxeberria I; Santamaría E; Rouzaut A; Enamorado M; Azpilikueta A; Inoges S; Bolaños E; Aznar MA; Sánchez-Paulete AR; Sancho D; Melero I
    Cancer Immunol Res; 2018 Jul; 6(7):798-811. PubMed ID: 29678874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
    Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
    Chacon JA; Sarnaik AA; Chen JQ; Creasy C; Kale C; Robinson J; Weber J; Hwu P; Pilon-Thomas S; Radvanyi L
    Clin Cancer Res; 2015 Feb; 21(3):611-21. PubMed ID: 25472998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination.
    Fromm G; de Silva S; Giffin L; Xu X; Rose J; Schreiber TH
    Cancer Immunol Res; 2016 Sep; 4(9):766-78. PubMed ID: 27364122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.
    Chen S; Fan J; Zhang M; Qin L; Dominguez D; Long A; Wang G; Ma R; Li H; Zhang Y; Fang D; Sosman J; Zhang B
    Nat Commun; 2019 Jan; 10(1):150. PubMed ID: 30635578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
    Zhao Y; Croft M
    Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo.
    Li Q; Ai J; Song Z; Liu J; Shan B
    Cell Mol Immunol; 2008 Oct; 5(5):379-84. PubMed ID: 18954562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.
    Guillerey C; Nakamura K; Pichler AC; Barkauskas D; Krumeich S; Stannard K; Miles K; Harjunpää H; Yu Y; Casey M; Doban AI; Lazar M; Hartel G; Smith D; Vuckovic S; Teng MW; Bergsagel PL; Chesi M; Hill GR; Martinet L; Smyth MJ
    JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31194697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses.
    Menk AV; Scharping NE; Rivadeneira DB; Calderon MJ; Watson MJ; Dunstane D; Watkins SC; Delgoffe GM
    J Exp Med; 2018 Apr; 215(4):1091-1100. PubMed ID: 29511066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
    Joseph AM; Srivastava R; Zabaleta J; Davila E
    Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8
    Aznar MA; Labiano S; Diaz-Lagares A; Molina C; Garasa S; Azpilikueta A; Etxeberria I; Sanchez-Paulete AR; Korman AJ; Esteller M; Sandoval J; Melero I
    Cancer Immunol Res; 2018 Jan; 6(1):69-78. PubMed ID: 29133290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
    Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
    J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-1BBL costimulation retrieves CD28 expression in activated T cells.
    Habib-Agahi M; Jaberipour M; Searle PF
    Cell Immunol; 2009; 256(1-2):39-46. PubMed ID: 19217084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral CD8
    Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
    Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.